Vitamin D3 for Aromatase Inhibitor Induced Arthralgias

Completed · Phase 2 · Has a placebo group

Conditions studied: Breast Cancer

In brief

The primary purpose is to determine if high dose vitamin D3 reduces the incidence of musculoskeletal symptoms associated with the aromatase inhibitor letrozole in women with early stage breast cancer and low serum vitamin D levels.

Key facts

Study ID

NCT00867217

Run by

Qamar Khan

People needed

160

Starts

2009-03-01

Expected to finish

2011-01-01

Last updated by the study team

2018-02-09

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Post-menopausal women newly diagnosed with early stage breast cancer, who would be treated with an aromatase inhibitor
• Serum 25OHD levels < 40 ng/ml

You may not qualify if…

• Severe or debilitating musculoskeletal pain
• Known metastatic disease
• History of renal stones
• History of hypercalcemia or hyperthyroidism
• Currently receiving adjuvant or neoadjuvant chemotherapy
• Currently receiving other investigational agents

Where it is running

• University of Kansas Medical Center — Westwood, Kansas, United States
• Cancer Centers of Kansas, P.A. — Wichita, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.